November 21, 2019 Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoons’ BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration Overall Deal Potential Valued up to $2.4B Read full article